HanAll Biopharma (KRX: 009420.KS) announced today that it had been restructured from the Jae-chun Yoon and Seung-kook Park joint representative system to a Seung-won Jeong joint representative system through the 48th general shareholders’ meeting and Board of Directors meeting. CEO Seung-kook Park, Ph.D. will oversee the company’s pharmaceutical business and domestic R&D, while newly appointed CEO Seung-won Jeong, M.D. will focus on new pipeline development through open innovation with domestic and international biopharmaceutical companies along with global clinical development. Former CEO Jae-chun Yoon will continue serving as chair of the Board of Directors of HanAll Biopharma.
CEO Seung-kook Park graduated from Seoul National University and obtained a PhD from KAIST. While working for 15 years at Daewoong Pharmaceutical, Park led the development of the “Easyef® Topical Solution”, a medicine for diabetic foot ulcer, as Korea’s first novel biologic drug. In 2007, he took office as director of the HanAll Biopharma Research Center and has been in charge of the development of HanAll Biopharma’s new biomedicines. Park has been serving in the position of CEO of HanAll Biopharma since 2013.
CEO Seung-won Jeong graduated from the Yonsei University College of Medicine, worked at the consulting firm Bain & Company, and obtained his MBA from MIT, the Sloan School of Management, in the U.S. He then joined the head office of Novartis and worked for 12 years in Switzerland, Korea, and Japan in charge of clinical development and business strategy development. Having overseen the regional osteoporosis business divisions for Japan and China at UCB since 2017, Jeong was appointed CEO of HPI, HanAll Biopharma’s U.S. subsidiary, in June of last year. He will be working at Boston office that is expected to open this year and serve as co-CEO of HanAll Biopharma and as CEO of the U.S. subsidiary.
NextHanAll Biopharma Appoints David Hernandez as Vice President of Clinical Development Operations
PrevHanAll Biopharma’s Chinese Partner HBM Initiates the First Dosing of Phase 3 in Dry Eye Disease